Are We Heading Toward a Recession?
Fears of a recession in 2025 grew at the end…
Sell
44
HRTS Quote, Financials, Valuation and Earnings
Last price:
$27.70
Seasonality move
:
1.11%
Day range:
$27.34 - $27.53
52-week range:
$25.32 - $36.03
Dividend yield:
0.52%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
742
Avg. volume:
8.7K
1-year change:
-16.11%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$27.34 | -- | -- | -- | $0.47 | 0.52% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.70 | -- | -- | -- | $0.15 | 0.82% | -- |
|
CANC
Tema Oncology ETF
|
$23.25 | -- | -- | -- | $0.73 | 2.15% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$26.50 | -- | -- | -- | $0.00 | 0% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$49.17 | -- | -- | -- | $0.33 | 5.73% | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
$25.15 | -- | -- | -- | $0.51 | 1.82% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 1.048 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.837 | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | 1.142 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.605 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.940 | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | 0.744 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | -- | -- | -- | -- | -- |
Tema GLP-1, Obesity & Cardiometabolic ETF vs. Competitors
-
Which has Higher Returns HRTS or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Global X Aging Population ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is HRTS or AGNG More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.536%.
-
Which is a Better Dividend Stock HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.52%. Global X Aging Population ETF offers a yield of 0.82% to investors and pays a quarterly dividend of $0.15 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns HRTS or CANC?
Tema Oncology ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Tema Oncology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- CANCTema Oncology ETF-- -- -- -
What do Analysts Say About HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Oncology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Tema Oncology ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Tema Oncology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 CANCTema Oncology ETF0 0 0 -
Is HRTS or CANC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Oncology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.52%. Tema Oncology ETF offers a yield of 2.15% to investors and pays a quarterly dividend of $0.73 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Tema Oncology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Tema Oncology ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Tema Oncology ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Tema Oncology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Tema Oncology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- CANCTema Oncology ETF-- -- -- --
-
Which has Higher Returns HRTS or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is HRTS or HTEC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.702%.
-
Which is a Better Dividend Stock HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.52%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns HRTS or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is HRTS or JDOC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.52%. JPMorgan Healthcare Leaders ETF offers a yield of 5.73% to investors and pays a quarterly dividend of $0.33 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
-
Which has Higher Returns HRTS or MEDX?
Horizon Kinetics Medical ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Horizon Kinetics Medical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- MEDXHorizon Kinetics Medical ETF-- -- -- -
What do Analysts Say About HRTS or MEDX?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Horizon Kinetics Medical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Horizon Kinetics Medical ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Horizon Kinetics Medical ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 MEDXHorizon Kinetics Medical ETF0 0 0 -
Is HRTS or MEDX More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Horizon Kinetics Medical ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or MEDX?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.52%. Horizon Kinetics Medical ETF offers a yield of 1.82% to investors and pays a quarterly dividend of $0.51 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Horizon Kinetics Medical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or MEDX?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Horizon Kinetics Medical ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Horizon Kinetics Medical ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Horizon Kinetics Medical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Horizon Kinetics Medical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- MEDXHorizon Kinetics Medical ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Is Butterfly Network the Best Small-Cap Stock?
Brought to public trading by an SPAC merger in early…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
